Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1999 Dec;14(12):711-7.
doi: 10.1046/j.1525-1497.1999.02229.x.

Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease

S R Majumdar  1 , J H Gurwitz, S B Soumerai
Affiliations
Comparative Study

Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease

S R Majumdar et al. J Gen Intern Med. 1999 Dec.

Abstract

Objectives: To determine adherence to national guidelines for the secondary prevention of coronary artery disease (CAD) using lipid-lowering drugs (LLDs), by studying the rate of use of LLDs, predictors of use, and the rate of achieving lipid goals, among eligible patients recently hospitalized with acute myocardial infarction.

Design: Cross-sectional analysis of 2,938 medical records, collected from July 1995 to May 1996.

Setting: Thirty-seven community-based hospitals in Minnesota.

Patients: The 622 patients had previously established CAD and hyperlipidemia (total cholesterol> 200 mg/dL or currently using LLDs), and were eligible for LLDs according to the National Cholesterol Education Program II (NCEP II) Guidelines.

Measurements: The use of LLDs in eligible patients (primary outcome) and successful achievement of NCEP II goals (total cholesterol <160 mg/dL) among treated patients (secondary outcome).

Main results: Only 230 (37%) of 622 eligible patients received LLDs. In multivariate logistic regression, factors independently related to LLD use included age greater than 74 years (adjusted odds ratio [AOR] 0.55; 95% confidence interval [CI] 0.35, 0.88) and severe comorbidity (AOR 0.60; 95% CI 0.38, 0.95), managed care enrollee (AOR 1.56; 95% CI 1.02, 2.39), past smoker (AOR 1.72; 95% CI 0.98, 3.01), prior revascularization (AOR 2.31; 95% CI 1.51, 3.53), and the use of aspirin (AOR 1.59; 95% CI 1.07, 2.38) or >/=4 medications (AOR 2.89; 95% CI 2.19, 3.84). Of the treated patients who had lipid levels measured (n = 149), 15% achieved the recommended goal of a total cholesterol below 160 mg/dL. Of the untreated patients (n = 392), 89% were discharged from hospital without a LLD prescription.

Conclusions: Lipid-lowering drugs, although proven effective for the secondary prevention of CAD, were used by only one third of eligible patients. Among patients receiving LLDs, few achieved recommended lipid goals. Directed quality improvement interventions, such as starting LLDs during hospitalization, may have the potential to substantially reduce CAD morbidity and mortality in this vulnerable population.

PubMed Disclaimer

Comment in

References

    1. Soumerai SB. Factors influencing prescribing. Aust J Hosp Pharm. 1988;18(3):9–16.
    1. Lamas GA, Pfeffer MA, Hamm P, et al. Do the results of randomized trials of cardiovascular drugs influence medical practice? N Engl J Med. 1992;327:241–7. - PubMed
    1. La Rosa JC, Hunninghake D, Bush D, et al. The cholesterol facts—a summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. Circulation. 1990;81:1721–33. - PubMed
    1. Gaziano JM, Hebert PR, Hennekens CH. Cholesterol reduction: weighing the benefits and risks. Ann Intern Med. 1996;124:914–8. - PubMed
    1. Kjekshus J, Pedersen TR, Tobert JA. Lipid lowering therapy for patients with or at risk of coronary artery disease. Curr Opin Cardiol. 1996;11:418–27. - PubMed

Publication types

Substances